| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.4 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |